Glenview Capital Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Glenview Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$83.14 - $145.99 $13.2 Million - $23.1 Million	-158,301 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $51,297 - $66,600	466 Added 0.3%	158,301 $18.8 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $4.34 Million - $6.46 Million	43,490 Added 38.03%	157,835 $21.8 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $32.7 Million - $45.9 Million	-330,356 Reduced 74.29%	114,345 $15.9 Million
Q2 2021 Aug 16, 2021	SELL	$65.78 - $105.02 $914,276 - $1.46 Million	-13,899 Reduced 3.03%	444,701 $43.2 Million
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $29.4 Million - $42.1 Million	458,600 New	458,600 $31.3 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $6.31 Million - $9.53 Million	-97,047 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$59.04 - $77.95 $1.37 Million - $1.82 Million	-23,285 Reduced 19.35%	97,047 $6.31 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $3.49 Million - $8.93 Million	120,332 New	120,332 $8.8 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Glenview Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Glenview Capital Management, LLC with notifications on news.